Perspectives on Enquiry & Evidence
FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?
The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.
February 2021: Updates from the CYTEL COVID-19 Trial Tracker
Cytel COVID Panel: Long-term Changes to Clinical Trials Due to the Pandemic
COVID-19 Trial Tracker Updates (January 11)
Year-end Roundup: Cytel’s Contributions Towards Health & Education in 2020
COVID-19 Trial Tracker Updates (December 8)
Mapping the Landscape of COVID-19 Clinical Trials in the US
Melinda Gates, on COVID-19 and Drug Development in Emerging Economies
Trial Tracker: State of COVID-19 Development (May 2020)
4 Things You Need to Know about COVID-19 Trial Designs
Weekly Insights from the COVID-19 Trial Tracker: Oxford Vacine Study
COVID-19: Trials, Designs and Tools for Promising Results - A Virtual Panel Discussion
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice